Yandong Wen

Yandong Wen

Auto-generated profile, based on publicly available information

Yandong Wen

Department of Chinese Medicine, Eye Hospital, China Academy of Chinese Medical Sciences

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019
Verified
Journal Article
Closed access
JKJ. Ke
J. Ke
BZB-H Zhang
B-H Zhang
YLY-Y Li
Y-Y Li
MZM. Zhong
M. Zhong
WMW. Ma
W. Ma
YCY-D Cai
Y-D Cai

1 December 2022
Verified
Closed access
XQXu Qing
Xu Qing
WYWang Yang
Wang Yang
LZLi Zhongyu
Li Zhongyu
YJYan Jiaxing
Yan Jiaxing
ZYZhao Yingpan
Zhao Yingpan
WYWen Yandong
Wen Yandong

28 September 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
YTYibing Tian
Yibing Tian
TZTai Zhang
Tai Zhang
BYBochao Yuan
Bochao Yuan
ZLZhongyu Li
Zhongyu Li
TCTing Chen
Ting Chen
YWYandong Wen
Yandong Wen
The process of chronic gastritis transforming into gastric cancer (GC) follows the classic Correa cascade, with persistent inflammation driving the stepwise transition from normal gastric mucosa through superficial gastritis, atrophic gastritis, intestinal metaplasia, dysplasia, and ultimately carcinoma. Among these stages, intestinal metaplasia and dysplasia occurring on an atrophic mucosal background are widely regarded as the most common gastric precancerous lesions (GPL) because of their pronounced carcinogenic risk. Chronic inflammation can induce epithelial–mesenchymal transition (EMT), thereby accelerating gastric malignant progression. In the GPL stage, the inflammatory gastric microenvironment commonly induces partial EMT (pEMT); importantly, this state is partly reversible and may be amenable to intervention to slow disease progression. As lesions advance, epithelial cells more fully undergo EMT, acquiring greater motility, invasiveness, and metastatic capability, which increases susceptibility to malignant conversion. MicroRNAs (miRNAs) are key molecular regulators in the transition from chronic gastritis to GC through EMT modulation. This review comprehensively discusses inflammation-driven EMT activation and functionally classifies pro-EMT oncomiRNAs (e.g., miR-21, miR-155) and anti-EMT tumor-suppressive miRNAs (e.g., miR-200 family, let-7 family, miR-34a), delineating a complex crosstalk network among inflammation, miRNA, and EMT. We further evaluate miRNAs as non-invasive biomarkers for early detection and prognosis of GPL and discuss emerging therapeutic strategies targeting the miRNA–EMT axis, including nanoparticle- or exosome-based delivery systems, miRNA antagonists, and miRNA sponges. Nevertheless, clinical application of circulating miRNAs remains limited by insufficient assay standardization and validation, incomplete target specificity, off-target effects, suboptimal delivery efficiency, and a lack of large-scale clinical evidence. By integrating molecular mechanisms and transformation status of miRNA-EMT axis in GPL, this review provides new insights for precision prevention and targeted intervention in gastric carcinogenesis.